Kailera Therapeutics (NASDAQ:KLRA) Shares Down 11% – Time to Sell?

Kailera Therapeutics, Inc. (NASDAQ:KLRA)’s share price was down 11% during trading on Tuesday . The company traded as low as $19.90 and last traded at $20.74. Approximately 392,649 shares were traded during mid-day trading, a decline of 52% from the average session volume of 815,587 shares. The stock had previously closed at $23.30.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on the company. JPMorgan Chase & Co. started coverage on Kailera Therapeutics in a report on Tuesday, May 12th. They set an “overweight” rating and a $30.00 price target on the stock. Jefferies Financial Group initiated coverage on Kailera Therapeutics in a research report on Tuesday, May 12th. They issued a “buy” rating and a $48.00 target price for the company. William Blair started coverage on shares of Kailera Therapeutics in a research note on Tuesday, May 12th. They set an “outperform” rating on the stock. TD Cowen initiated coverage on shares of Kailera Therapeutics in a report on Tuesday, May 12th. They set a “buy” rating and a $57.00 price target on the stock. Finally, Zacks Research upgraded shares of Kailera Therapeutics to a “hold” rating in a research note on Wednesday, May 13th. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $42.75.

Kailera Therapeutics Stock Performance

The stock has a market capitalization of $2.86 billion and a P/E ratio of -0.01. The firm has a fifty day simple moving average of $21.50.

Kailera Therapeutics (NASDAQ:KLRA) last posted its earnings results on Tuesday, May 26th. The company reported ($3,650.00) earnings per share for the quarter.

Insider Transactions at Kailera Therapeutics

In other Kailera Therapeutics news, major shareholder Rtw Investments, Lp acquired 500,000 shares of the company’s stock in a transaction that occurred on Monday, April 20th. The shares were bought at an average price of $16.00 per share, with a total value of $8,000,000.00. Following the completion of the acquisition, the insider owned 10,776,820 shares in the company, valued at $172,429,120. This represents a 4.87% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Andrew T. Kaplan bought 8,398,438 shares of the business’s stock in a transaction that occurred on Monday, April 20th. The shares were acquired at an average price of $16.00 per share, with a total value of $134,375,008.00. Following the completion of the transaction, the director directly owned 26,255,581 shares of the company’s stock, valued at $420,089,296. This trade represents a 47.03% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have acquired 10,460,938 shares of company stock worth $167,375,008 in the last quarter.

About Kailera Therapeutics

We are an advanced clinical-stage biotechnology company focused on elevating the next era of obesity care by advancing a diversified pipeline to provide options for people living with obesity no matter where they are in their treatment journey. Obesity is a chronic, progressive and debilitating disease that impacts over 1 billion people globally and requires long-term comprehensive treatment. Since obesity is the driving factor for more than 200 comorbidities and represents a significant contributor to increased morbidity and mortality, our vision is to deliver category-leading obesity management medications that give people the power to restore their health and transform their lives.